For more than 60 years, Ipca has been partnering healthcare globally in over 110 countries and in markets as diverse as Africa, Asia, Australia, Europe and the US.
Ipca is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 APIs for various therapeutic segments.
We are one of the world's largest manufacturers and suppliers of over a dozen APIs. These are produced right from the basic stage at manufacturing facilities endorsed by the world's most discerning drug regulatory authorities like US-FDA, UK-MHRA, EDQM-Europe, WHO-Geneva and many more.
Ipca is a therapy leader in India for anti-malarials with a market-share of over
34% with a fast expanding presence in the international market as well. We also lead in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for rheumatoid arthritis. We have leading brands in 5 therapeutic areas, with 4 of our branded formulations being ranked among the Top-300 Indian brands by ORG-IMS.
Our international client roster includes global pharmaceutical giants like AstraZeneca, GlaxoSmithKline, Merck, Roche and Sanofi Aventis; most of whom we have been partnering over the years.
At Ipca, quality assurance is an attitude of seeking sustainable betterment in every aspect of our work. The results show in our financials as well as work ethic. Net income for the financial year ended 31st March 2010 was
Rs. 1,559 Crores. Net profit was Rs. 209 Crores.
What's more, Ipca was awarded as 'Among the 100 Best Companies to Work in India 2010' in a study conducted by Great Place to Work® - India in joint collaboration with The Economic Times.
manufacturers and suppliers of
over a dozen APIs
by the world's leading drug
Companies to Work in India 2010'